Dr. Levy on Entrectinib in Oncogene-Driven NSCLC

Benjamin P. Levy, MD
Published: Thursday, Mar 28, 2019



Benjamin P. Levy, MD, assistant professor of oncology, clinical director of Medical Oncology, Sidney Kimmel Cancer Center and Johns Hopkins Medicine, discusses the use of entrectinib in patients with oncogene-driven non–small cell lung cancer (NSCLC).

Entrectinib is yet another targeted agent that’s making its way into the NSCLC space. It’s use is currently being evaluated in patients with advanced-stage disease who harbor NTRK fusions or ROS1 rearrangements, Levy says. In the NTRK space, recent studies show an approximate 55% response rate and a progression-free survival benefit ranging from 10 to 12 months with entrectinib. However, larotrectinib (Vitrakvi) has already received FDA approved for the treatment of all solid tumors that harbor these rare mutations, so where entrectinib will fit into this complex space remains to be seen.

In ROS1-rearranged tumors, the STARTRK trials have demonstrated a response rate of about 70% to 75% with entrectinib, Levy adds. Although the agent does not appear to have benefit in patients who were previously treated with crizotinib (Xalkori), it does induce benefit in targeted therapy-naïve patients.

In February 2019, the FDA granted a priority review designation to a new drug application for entrectinib for the treatment of select adult and pediatric patients with NTRK fusion-positive locally advanced or metastatic solid tumors, as well as patients with metastatic ROS1-positive NSCLC.
SELECTED
LANGUAGE


Benjamin P. Levy, MD, assistant professor of oncology, clinical director of Medical Oncology, Sidney Kimmel Cancer Center and Johns Hopkins Medicine, discusses the use of entrectinib in patients with oncogene-driven non–small cell lung cancer (NSCLC).

Entrectinib is yet another targeted agent that’s making its way into the NSCLC space. It’s use is currently being evaluated in patients with advanced-stage disease who harbor NTRK fusions or ROS1 rearrangements, Levy says. In the NTRK space, recent studies show an approximate 55% response rate and a progression-free survival benefit ranging from 10 to 12 months with entrectinib. However, larotrectinib (Vitrakvi) has already received FDA approved for the treatment of all solid tumors that harbor these rare mutations, so where entrectinib will fit into this complex space remains to be seen.

In ROS1-rearranged tumors, the STARTRK trials have demonstrated a response rate of about 70% to 75% with entrectinib, Levy adds. Although the agent does not appear to have benefit in patients who were previously treated with crizotinib (Xalkori), it does induce benefit in targeted therapy-naïve patients.

In February 2019, the FDA granted a priority review designation to a new drug application for entrectinib for the treatment of select adult and pediatric patients with NTRK fusion-positive locally advanced or metastatic solid tumors, as well as patients with metastatic ROS1-positive NSCLC.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20192.0
Oncology Consultations®: The Advancing Role of CAR T-Cell Therapies in Hematologic MalignanciesApr 30, 20191.5
Publication Bottom Border
Border Publication
x